Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | Director · President & CEO | May 15, 2026 | May 19, 2026 |
| Sotera Health CoSHC · Entity 3869 | Director | May 22, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 444,704 |
Last balance in matching sequence
After 2026-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 9,681 · Balance 366,360 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Row 2 · 2026-05-15 · Grant · Acquired 78,344 · Balance 444,704 F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Sotera Health Co
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per share ("Common Stock")SEC Table I · non-derivative | Direct | 34,102 |
Reported balance
After 2026-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 14,970 · Balance 34,102 F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2: These securities consist of 14,970 RSUs and 19,132 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date.
F2: These securities consist of 14,970 RSUs and 19,132 shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 19, 2020 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,008 | $100.44 | $101,243.52 |
DisclosureSEC source: 0001127602-20-017282 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,757 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported as well as 193 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2020. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 50,869 | $137.43 | $6,990,926.67 |
DisclosureSEC source: 0001127602-19-027191 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,572 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on August 15, 2019. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 20:41 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 114,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026736 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,441 F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on August 16, 2016, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from August 4, 2016 to August 4, 2019, as certified by the Compensation Committee of the Board of Directors on August 14, 2019. The award is subject to the reporting person's continued service through the vesting date of August 16, 2019. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 21:47 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 5,008 | $121.79 | $609,924.32 |
DisclosureSEC source: 0001127602-19-023747 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,143 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,248 | $109.37 | $136,493.76 |
DisclosureSEC source: 0001127602-19-021559 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,151 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 20:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,834 | $103.38 | $292,978.92 |
DisclosureSEC source: 0001127602-19-021234 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,399 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 23, 2019 Filed May 24, 2019 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 24,412 | $99.39 | $2,426,308.68 |
DisclosureSEC source: 0001127602-19-019895 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,233 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the performance share units reported above. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 22, 2019 Filed May 24, 2019 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 53,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019895 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,645 F1 · shares: Represents shares earned from performance share unit awards granted to the reporting person on June 29, 2016 and July 26, 2017 with performance periods ending on March 30, 2019, based on achievement of 80.05% and 144.31% of their respective internal financial and performance metric targets, as certified by the Compensation Committee of the Board of Directors effective May 22, 2019. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 48,971 | $0.00 Strike: $98.03 | $0.00 |
DisclosureSEC source: 0001127602-19-018731 · form4.xml · derivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,971 Underlying: Common Stock · 48,971 shares Expires 2026-05-14 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 14, 2019 Filed May 16, 2019 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 14,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-018731 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,991 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 57,587 | $94.51 | $5,442,547.37 |
DisclosureSEC source: 0001127602-19-018581 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,964 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on April 25, 2019. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported as well as 234 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2019. Read SEC document |
| April 23, 2019 Filed Apr 25, 2019 21:09 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 131,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016241 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,317 F1 · kind: Represents shares earned from a performance share unit award granted to the reporting person on June 29, 2016, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from April 3, 2016 to March 30, 2019, as certified by the Compensation Committee of the Board of Directors on April 23, 2019. The award is subject to the reporting person's continued service through the vesting date of May 10, 2019. F2 · balance_after: This number includes unvested restricted stock units previously reported as well as 141 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2018. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 5,139 | $89.31 | $458,964.09 |
DisclosureSEC source: 0001127602-18-022831 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,126 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 40,443 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020831 · form4.xml · derivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,443 Underlying: Common Stock · 40,443 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 11,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020831 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,265 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,941 | $92.73 | $179,988.93 |
DisclosureSEC source: 0001127602-18-020480 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,904 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 29, 2017 Filed May 23, 2018 20:57 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 3,595 | $40.39 | $145,202.05 |
DisclosureSEC source: 0001127602-18-018564 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,845 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported as well as 754 shares and 303 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2017 and April 30, 2018, respectively. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 104,516 | $41.64 Strike: $41.64 | $4,352,046.24 |
DisclosureSEC source: 0001127602-17-020973 · form4.xml · derivative · entry 2 Simon, Christopher · CIK 0001674993 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,516 Underlying: Common Stock · 104,516 shares Expires 2024-06-06 F2 · derivative.exercise_date: Grants of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:07 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 25,516 | $41.64 | $1,062,486.24 |
DisclosureSEC source: 0001127602-17-020973 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,383 F1 · shares: Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.